BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up [Yahoo! Finance]
Instil Bio, Inc. (TIL)
NASDAQ:AMEX Investor Relations:
nasdaq.com/symbol/til
Company Research
Source: Yahoo! Finance
With the acquisition, BNTX will gain full global rights to BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A, which is currently being developed in mid-to-late-stage studies for various oncological indications. The transaction is expected to be closed in the first quarter of 2025, subject to the fulfillment of customary closing conditions, including regulatory approvals. Shares of BioNTech were up 4.9% on Nov. 13 following the announcement of the news. The stock has risen 5.6% so far this year against the industry's decline of 3.8%. Image Source: Zacks Investment Research We remind investors that in November 2023, Germany-based BioNTech signed an exclusive license and collaboration agreement with Biotheus. The agreement granted BNTX the rights to develop, manufacture and commercialize BNT327/PM8002 worldwide, excluding Greater China. With the acquisition of Biotheus, BioNTech gets full global rights to the candidate The latest deal is likely
Show less
Read more
Impact Snapshot
Event Time:
TIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TIL alerts
High impacting Instil Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TIL
News
- Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast CancerGlobeNewswire
- Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? [Yahoo! Finance]Yahoo! Finance
- Summit boosts Instil, BioNTech as lead drug beats Merck's Keytruda [Seeking Alpha]Seeking Alpha
- Futures Gain As Expectations For A 50bps Rate Cut Spike [zero hedge]zero hedge
TIL
Earnings
- 11/13/24 - Miss
TIL
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/13/24 - Form S-3
- TIL's page on the SEC website